{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:50:24Z","timestamp":1778687424263,"version":"3.51.4"},"reference-count":58,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1430,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1600-0609.2011.01689.x","type":"journal-article","created":{"date-parts":[[2011,8,4]],"date-time":"2011-08-04T20:08:33Z","timestamp":1312488513000},"page":"381-393","source":"Crossref","is-referenced-by-count":28,"title":["Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review"],"prefix":"10.1111","volume":"87","author":[{"given":"Shantashri","family":"Vaidya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanjaksha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babu Rao","family":"Vundinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,2]]},"reference":[{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/B0-12-227555-1\/00162-3","article-title":"Chronic myelogenous leukemia: etiology, incidence, and clinical features","volume":"1","author":"Clarkson","year":"2002","journal-title":"Encycl Cancer"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr\/abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiolody of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"issue":"4 Suppl.","key":"10.1111\/j.1600-0609.2011.01689.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S1471-4914(02)02305-5","article-title":"STI571 (Gleevec) as a paradigm for cancer therapy","volume":"8","author":"Druker","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF03256446","article-title":"Anticipating clinical resistance to target-directed agents: the BCR-ABL paradigm","volume":"10","author":"Azam","year":"2006","journal-title":"Mol Diagn Ther"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1368-7646(03)00062-1","article-title":"Resistance to imatinib (Glivec): update on clinical mechanisms","volume":"6","author":"Weisberg","year":"2003","journal-title":"Drug Resist Updat"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1042\/BST0351347","article-title":"Characterization of cancer stem cells in chronic myeloid leukaemia","volume":"35","author":"Jorgensen","year":"2007","journal-title":"Biochem Soc Trans"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB14|cit14","unstructured":"Larghero J Mahon FX Madeleine-Chambrin I et\u00a0al. Elevated levels of the plasma protein alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis mediate pharmacological resistance to Gleevac (STI571, imatinib) in vitro and are associated with primary resistance in vivo"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergencyto.2005.01.015","article-title":"Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid myeloid leukaemia during imatinib treatment","volume":"162","author":"Galimberti","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukaemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1182\/blood-2003-01-0083","article-title":"Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro","volume":"102","author":"Ferrao","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cellsig.2011.02.005","article-title":"Activation of STAT 5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1","volume":"23","author":"Yamada","year":"2011","journal-title":"Cell Signal"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR\/ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic myeloid leukaemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL","volume":"11","author":"Nardi","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI-571; a prospective study","volume":"359","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB23|cit23","article-title":"Mechanisms of resistance, common BCR-ABL mutations, and monitoring response to treatment in CML","author":"Hughes","year":"2008","journal-title":"Medscape"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR\/ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3324\/haematol.2009.007864","article-title":"Detection of twelve nucleotide insertions in the BCR\/ABL kinase domain in an imatinib resistant but dasatinib sensitive patient with bi-phenotypic acute leukemia","volume":"94","author":"Hayette","year":"2009","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1038\/sj.onc.1208796","article-title":"Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia","volume":"24","author":"Barnes","year":"2005","journal-title":"Oncogene"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to theABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant BCR\/ABL","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcome mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem Biol Drug Des"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB37|cit37","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB38|cit38","first-page":"11","article-title":"Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML)","volume":"110","author":"Cortes-Franco","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2006-02-005579","article-title":"Activation of a novel Bcr\/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells","volume":"109","author":"Bartholomeusz","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10570-009-9375-0","article-title":"Effective targeting of quiescent chronic myelogenous leukemic stem cells by histone deacetylase inhibitors in combination with imatinib mesylate cancer","volume":"17","author":"Zhang","year":"2010","journal-title":"Cell"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2004-03-0849","article-title":"Activation of the PI3K\/mTOR pathway by BCR\/ABL contributes to increased production of reactive oxygen species","volume":"105","author":"Kim","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB45|cit45","first-page":"941","article-title":"DNA vaccination against bcr-abl positive cells in mice","volume":"35","author":"Lucansky","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","article-title":"Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpointfusion peptides generates specific immune responses","volume":"95","author":"Pinilla-Ibarz","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/blood-2002-12-3899","article-title":"Inhibition of BCR\/ABL gene expression by small interfering RNA sensitizes for imatinib mesylate (STI-571)","volume":"2","author":"Wohlbold","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/asheducation-2003.1.132","article-title":"Chronic myeloid leukemia","volume":"1","author":"Melo","year":"2003","journal-title":"Am Soc Hematol"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.leu.2401677","article-title":"Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems","volume":"14","author":"Clark","year":"2000","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB50|cit50","first-page":"745","article-title":"BCR\/ABL and BCR proteins: biochemical characterization and localization","volume":"4","author":"Dhut","year":"1990","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V85.8.2162.bloodjournal8582162","article-title":"Multi-Unit Ribozyme-Mediated Cleavage of bcr-abl mRNA in Myeloid Leukemias","volume":"85","author":"Leopold","year":"1995","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood-2003-03-0811","article-title":"Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571","volume":"102","author":"Beissert","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","article-title":"Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase","volume":"7","author":"Vigneri","year":"2001","journal-title":"Nat Med"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB54|cit54","first-page":"89","volume-title":"Chronic Myeloid Leukemia","author":"Parikh","year":"2007"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB55|cit55","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2011.04.002","article-title":"Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase","author":"Rosti","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1548-5315(12)70039-6","article-title":"First-line treatment of chronic myeloid leukemia: imatinib versus nilotinib and dasatinib","volume":"8","author":"DiBella","year":"2011","journal-title":"Commun Oncol"},{"key":"10.1111\/j.1600-0609.2011.01689.x-BIB58|cit58","unstructured":"Nelson R Bosutinib effective as second- and third-line therapy in CML"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01689.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01689.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T05:33:50Z","timestamp":1625636030000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01689.x"}},"subtitle":["A review on drug resistance mechanisms in CML"],"short-title":[],"issued":{"date-parts":[[2011,10,2]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01689.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10,2]]}}}